Supernus Pharmaceuticals Inc. (SUPN), a revenue-generating biopharmaceutical company developing medicines for the treatment of central nervous system diseases, has a regulatory catalyst to watch next month.
The FDA decision on SPN-830, the company's investigational apomorphine infusion device for the continuous treatment of motor fluctuations ("OFF" episodes) in Parkinson's disease, is expected on February 1, 2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com